CytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Ltd is a Singapore-headquartered biotechnology company listed on NASDAQ under the ticker GDTC. The company is focused on pre-clinical research and development of cell-based immunotherapies for cancers and certain degenerative conditions, with activities in Malaysia and Singapore. Its pipeline includes CTM-N2D, a gamma delta T-cell therapy that is being tested in Phase I studies, as well as iPSC-gdNKT, CTM-GDT, and CTM-MSC, each aimed at different therapeutic applications. CytoMed has research and clinical collaboration agreements with Sengkang General Hospital and SunAct Cancer Institute Private Limited to support studies involving CTM-MSC and CTM-GDT.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GDTC
|
$0.86
|
-12.5% Downside
|
Fair
|
$4.16
|
324.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 13, 2026
|
2.3x
|
17.2x
|
11.596 M
|
10.503 M
|
3.4%
|
29.5%
|
0.6
|
108.9%
|
